About BioNTech SE
BioNTech is a German biotechnology company that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
Milestones
Milestones as listed on biontech.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on biontech.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on biontech.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Pfizer-BioNTech COVID-19 vaccine
COVID-19 vaccine developed in 2020 under Project Lightspeed; a variant-adapted version followed in 2022.
Source: biontech.comPD-L1 x VEGF-A bispecific antibody candidate
In pivotal trials in lung cancer; partnered with Bristol Myers Squibb in 2025.
Source: biontech.comHER2-targeting ADC candidate
Antibody-drug conjugate in a pivotal Phase 3 trial in metastatic breast cancer.
Source: biontech.comIndividualized mRNA cancer immunotherapy
Personalised mRNA cancer immunotherapy approach tested in first-in-human trials.
Source: biontech.comPipeline & Regulatory Record
What public registers list for BioNTech SE: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.
Clinical trials 30 in our ClinicalTrials.gov registers · 2 in the EU register
Showing 10 of 30, trials with Irish sites first. The full lists are on the sponsor pages below.
All trials by sponsor name 1 registry name
Drugs in these trials 29 compounds
EU trials register (CTIS) 2 authorised or ongoing
- A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer2025-524445-27-00 · Phase III · Authorised
- A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease2025-521884-12-00 · Phase III · Ongoing
Group (BioNTech SE): founded 2008, headquarters Mainz, website biontech.de. Wikidata Q30256699 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here BioNTech SE; BioNTech Cell & Gene Therapies GmbH; BioNTech Manufacturing GmbH. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports BioNTech SE files with the US Securities and Exchange Commission (20-F, IFRS), in EUR as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | €2.87bn | €2.10bn | 73.3% | −€1.14bn | 20-F 2026 |
| Dec 2024 | €2.75bn | €2.25bn | 81.9% | −€665m | 20-F 2026 |
| Dec 2023 | €3.82bn | €1.78bn | 46.7% | €930m | 20-F 2026 |
| Dec 2022 | €17.31bn | €1.54bn | 8.9% | €9.43bn | 20-F 2025 |
| Dec 2021 | €18.98bn | €949m | 5.0% | €10.29bn | 20-F 2024 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.